31523-05-4

Basic information

• Product Name: 5-amino-3,3-dimethylindolin-2-one
• Synonyms: 5-amino-3,3-dimethylindolin-2-one;5-Amino-3,3-dimethyl-1,3-dihydro-1,3-dihydro-indol-2-one;5-amino-3,3-dimethyl-1H-indol-2-one
• CAS NO: 31523-05-4
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.218
• Mol File: 31523-05-4.mol

Chemical Properties

• Boiling Point: 383°C at 760 mmHg
• Flash Point: 185.5°C
• Appearance: /
• Density: 1.161
• Vapor Pressure: 4.52E-06mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 5-amino-3,3-dimethylindolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-3,3-dimethylindolin-2-one(31523-05-4)
• EPA Substance Registry System: 5-amino-3,3-dimethylindolin-2-one(31523-05-4)

Safety Data

• Hazardous Substances Data: 31523-05-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-amino-3,3-dimethylindolin-2-one is used as a chemical intermediate for the synthesis of various organic compounds and potential drug candidates due to its unique structure and potential biological activities.
Further research and studies are required to fully understand the potential applications and biological activities of 5-amino-3,3-dimethylindolin-2-one, which may lead to its use in different therapeutic areas within the pharmaceutical industry.

InChI:InChI=1/C10H12N2O/c1-10(2)7-5-6(11)3-4-8(7)12-9(10)13/h3-5H,11H2,1-2H3,(H,12,13)

Upstream product

• 100510-98-3 N-(3,3-dimethyl-2-oxo-indolin-5-yl)-acetamide 
• 19155-24-9 3,3-dimethyloxindole 
• 1504-06-9 3-methylindolin-2-one 
• 20870-79-5 5-nitrooxindole 
• 100511-00-0 1,3-Dihydro-3,3-dimethyl-5-nitro-2H-indol-2-one 

Downstream Products

• 125089-31-8 N-(3,3-dimethyl-2-oxo-indolin-5-yl)-benzamide 

Relevant articles and documents

Kinase inhibitors (by machine translation)

The present invention relates to certain 4 - (substituted anilino) -2 - (substituted piperi -1 -yl) pyrimidine -5 - carboxamide compounds useful for the treatment or prevention of diseases or medical conditions mediated by signal transduction of CaMMK1 isotype. For example, such compounds and salts thereof may be used to treat or prevent a variety of different cancers. Diseases (including 2 diabetes) and/or immune-mediated diseases. (by machine translation)

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability

Aurora kinase inhibitors have attracted a great deal of interest as a new class of antimitotic agents. We report a novel class of Aurora inhibitors based on a pentacyclic scaffold. A prototype pentacyclic inhibitor 32 (AKI-001) derived from two early lead

Pentacyclic kinase inhibitors

The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.

Pyrrolobenzimidazoles for treating heart or circulatory diseases

Pyrrolobenzimidazoles, processes for the preparation thereof and pharmaceutical compositions thereof for the treatment of coronary insufficiencies, cardiac failure, blood circulatory disturbances and occlusive diseases. The new pyrrolobenzimidazoles are of the formula STR1 wherein R1 is hydrogen, alkyl, alkenyl or cycloalkyl, R2 is hydrogen, alkyl, alkenyl, cyano or a substituted carbonyl or R1 and R2 together represent cycloalkylene or form alkylidene or cycloalkylidene, X is a valency bond, C1 -C4 alkylene or vinylene, T is oxygen or sulphur and Py is pyridyl or substituted pyridyl and including the tautomers thereof and the physiologically acceptable salts thereof.